Apresentação: Marinã Ramthum do Amaral R4 UTI Pediátrica – HRAS
Tipifarnib is Highly Active in HRAS-mutant Head and Neck … · 2018. 11. 6. · Prenylated...
Transcript of Tipifarnib is Highly Active in HRAS-mutant Head and Neck … · 2018. 11. 6. · Prenylated...
*** *** ** *
Prenylated
Unprenylated
UMSCC17B ORL214
Tipifarnib deprenylates HRAS in vivo
Tipifarnib is Highly Active in HRAS-mutant Head and Neck Squamous Cell Carcinoma (HNSCC) Tumor Models Mara Gilardi2, Zhiyong Wang2, Linda Kessler1, Antonio Gualberto1, Yi Liu1, J. Silvio Gutkind2, Francis Burrows1
1Kura Oncology, Inc., San Diego, CA, USA, 2University of California, San Diego
Tipifarnib is a potent and selective inhibitor of farnesyltransferase (FT). FTcatalyzes the post-translational attachment of farnesyl groups to signalingproteins that are requisite for localization to the inner cell membrane.Although all RAS isoforms are FT substrates, only HRAS is exclusivelydependent upon farnesylation for membrane localization and signalingactivation, making HRAS mutant tumors uniquely susceptible to tipifarnibmediated inhibition of FT. Based upon this rationale, the safety and efficacyof tipifarnib is currently being evaluated in patients with HRAS mutant headand neck squamous cell carcinoma (HNSCC) in an international, multicenter,open-label 2 cohort, non-comparative, pivotal Phase 2 trial (NCT03719690).Here we report the characterization of tipifarnib in CDX and PDX models ofHRAS-mutant HNSCC in vitro and in vivo
BACKGROUND AND RATIONALE
• HRAS is a targetable oncogene in squamous cell carcinomas using tipifarnib• Tipifarnib prevents HRAS prenylation and membrane insertion• HRAS-mutant cells are highly sensitive in vitro under both adherent and
anchorage-independent conditions• Tipifarnib induced stasis or regression in HRAS-mutant HNSCC xenograft
models, independently of HRAS genotype• Antitumor activity in vivo is associated with inhibition of MAPK and PI3K-
mTOR signaling, cell cycle arrest and robust activation of apoptosis• Direct antitumor effects may be enhanced by antiangiogenic activity of
tipifarnib in vivo• Tipifarnib is under active clinical evaluation in HRAS-mutant SCC including
HNSCC
CONCLUSIONS
TIPIFARNIB IS SELECTIVELY CYTOTOXIC TO HRAS-MUTANT HNSCC CELLS IN VITRO
Poster PB-083, EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium November13-16th, 2018
HRAS MUTATIONS DEFINE A UNIQUE MOLECULAR SUBSET OF HNSCC
NRASKRAS
Molecular basis of tipifarnib activity in HRAS-mutant HNSCC
TIPIFARNIB DEPRENYLATES AND DISPLACES HRAS FROM MEMBRANES
• HNSCC express high levels of HRAS2
• HRAS mutant SCCHN (~6% at initial diagnosis) characterized by frequent CASP8 mutations and low rate of TP53 mutation3
• HRAS mutation may result from toxin (e.g. tobacco) exposure4
• HRAS mutation is associated with innate and acquired resistance to cetuximab5
– 3/13 (23%) of patients with on-treatment disease progression during cetuximab/platinum/5-FU therapy acquired HRAS mutations
1
1. TCGA data. Gao et al. 2013. Sci Signal 6:pl1; Cerami et al 2012. Cancer Discov. 2:401-42. Cancer Genome Atlas Network 2015. Nature 517:576-82.3. Cancer Genome Atlas Research Network 2012. Nature 489:519-254. Sathyan et al. 2007. Modern Path 20, 1141-85. Braig et al. Oncotarget. 2016. 7, 42988-42995
1
HRAS colocalization with cellular membranes is lost in tipifarnib-treated HNSCC cells
Control Tipifarnib
TIPIFARNIB IS HIGHLY ACTIVE IN HRAS-MUTANT HNSCC XENOGRAFTS
10-3 10-2 10-1 100 101 1020
20
40
60
80
100
120
HN30HN31ORL48
ORL214
CAL27
UMSCC17B
0
Cell
Viab
ility
%
Drug concentration (µM)
HRAS-mutant UMSCC17B and ORL214 cellswere treated with tipifarnib (100nM, 48h) andstained with anti-HRAS antibodies by westernblotting (left) or immunofluorescence (right).The fluorescence profile relative to thedistribution of HRAS (green) was compared tothat of DAPI (blue) and the membrane markerWGA lectins (red) by confocal microscopy
HNSCC cells were treated with a titration of tipifarnib for 72 h (left panel) or with vehicle or 300 nM tipifarnib under anchorage-independent conditions for 14 days (right panels)
MUTANT WILD TYPEUMSCC17B ORL48
ORL214 CAL27HN30HN31
HRAS
UMSCC17B
Vehicle
Tipifarnib
ORL2140 5 10 15 200
200
400
600
800VehicleTipifarnib
UMSCC17B (HRAS Q61L)
***
0 10 20 30 (days)0
200
400
600 ORL214 (HRAS G12C)
VehicleTipifarnib
***
Ctrl
H&E
Vehicle
Tipifarnib
Vehicle
Tipifarnib
VehicleTipifarnib
H&E
UMSCC17B
ORL214
Tum
or vo
lum
e (m
m3 )
Treatment time (days) ***p < 0.01
0 5 10 15 200
200
400
600
800VehicleTipifarnib
UMSCC17B (HRAS Q61L)
***
0 10 200
200
400
600 ORL214 (HRAS G12C)
***
All animals dosed orally at 60mg/kg BID
HNSCC TCGA (N=30)
0
500
1000
0 10 20 30 40
BL3325Q61L
All animals dosed orally at 80mg/kg BIDTreatment time (days)
HNSCC
VehicleTipifarnib
LSCC
Urothelialcancer
0
1000
2000
0 10 20 30
HN1420A146T
0
500
0 10 20
HN2579G12S
0
500
1000
0 10 20
HN2581G13R
Tum
or v
olum
e (m
m3 )
0
500
1000
0 10 20 30
LU1513Q61K
0
500
0 10 20 30
HN3504K117N
TIPIFARNIB INHIBITS ANGIOGENESIS IN VITRO AND IN VIVO
ACTIVITY OF TIPIFARNIB IN HRAS-MUTANT SCC IS INDEPENDENT OF GENOTYPE
TIPIFARNIB INHIBITS ONCOGENIC SIGNALING AND PROLIFERATION ANDINDUCES APOPTOSIS IN HRAS-MUTANT HNSCC XENOGRAFTS IN VIVO
pS6
pERK
Ctrl TipiUMSCC17B
ORL214
pS6
Ctrl
pERK
Tipi
% p
ERK
020406080
UMSCC17B CTRLUMSCC17B Tipifarnib
020406080
% p
S6
020406080
100
% p
ERK
020406080
100
% p
S6
ORL214 CTRLORL214 Tipifarnib
Ctrl Tipi
Clea
ved
Cas3
Ki67
UMSCC17B
Ctrl Tipi
Clea
ved
Cas3
Ki67
ORL214
**
**
020406080
% P
rolif
erat
ion
010203040
% A
popt
osis
UMSCC17B CTRLUMSCC17B Tipifarnib
01020304050
% P
rolif
erat
ion
0
10
20
30
40
% A
popt
osis
ORL214 CTRLORL214 Tipifarnib
***p < 0.001
*NS
**p < 0.01
***
***
***
***
**
**
*
**
2D monolayer assay 3D sphere formation assay
***p < 0.0001
*p < 0.01
**p < 0.011
UMSCC17B ORL214
0
10
20
30
% C
D31
***
% C
D31
0
10
20
30
40
***
VehicleTipifarnib
0
2
4
6
8
# B
ranc
hes
/ RO
I
VehicleTipifarnib
CTRL Tipifarnib
In vivo vessel densityIn vitro tube formation